The FDA-labeled starting dose of tirzepatide is 2.5 mg once weekly, given as a subcutaneous injection. This initiation dose is the same for both Mounjaro, the version approved for type 2 diabetes, and Zepbound, the version approved for chronic weight management. It is a tolerability dose and is typically increased after four weeks under clinician supervision.
What Tirzepatide Is
Tirzepatide is a once-weekly injection that activates two gut hormone receptors: GLP-1 and GIP. This dual action helps lower blood sugar and reduce appetite. It is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Both use the same active ingredient at the same starting dose.
The Standard Titration Schedule
FDA labels for Mounjaro and Zepbound describe a stepwise titration intended to reduce gastrointestinal side effects. The table below summarizes the labeled schedule. Your clinician may adjust this pace based on tolerance and goals.
| Week | Labeled Dose | Purpose |
|---|---|---|
| Weeks 1-4 | 2.5 mg once weekly | Initiation and tolerability |
| Weeks 5-8 | 5 mg once weekly | First maintenance dose |
| Weeks 9-12 | 7.5 mg once weekly | Further titration, if needed |
| Weeks 13+ | 10 mg, 12.5 mg, 15 mg | Step-up in 4-week intervals to a personalized maintenance dose |
Why the Starting Dose Matters
The starting dose exists to let the body adapt. GLP-1 and GIP receptor activation slows gastric emptying and influences satiety. Jumping straight to a high dose often causes nausea, vomiting, or diarrhea intense enough to make people stop therapy. Starting at 2.5 mg reduces dropout and gives clinicians a window to check tolerance before advancing.
Who May Not Tolerate a Straight 2.5 mg Start
Some people experience significant nausea even at 2.5 mg. Others have a history of gastroparesis, gallbladder disease, or pancreatitis that calls for extra caution. A clinician may pause titration, extend the initiation period, or recommend a different therapy. Self-adjusting the dose without input from your prescriber is not advised.
What the Clinical Trials Showed
The SURMOUNT-1 trial, published in the New England Journal of Medicine, evaluated tirzepatide at 5 mg, 10 mg, and 15 mg once weekly for chronic weight management in adults without diabetes. Mean weight reductions ranged from about 15 percent to 21 percent over 72 weeks, depending on dose. The 2.5 mg starting dose was not a primary study arm because it is an initiation step.
Side Effects Commonly Seen at Initiation
Even at 2.5 mg, some people notice:
- Nausea, especially after the first few doses
- Mild diarrhea or constipation
- Decreased appetite and smaller portion sizes
- Fatigue or headache during the first week
- Injection-site reactions such as redness or itching
Serious but less common warnings on the label include pancreatitis, gallbladder disease, acute kidney injury from dehydration due to vomiting, and a boxed warning about thyroid C-cell tumors observed in rodents.
How the Starting Dose Fits Into a Bigger Plan
Medication is only part of metabolic care. If you are weighing tirzepatide as part of a broader plan, review our treatment overview and our diet and nutrition guide. Nutrition and activity changes help the medication work and may reduce side effects. If your starting point is an elevated A1C, our A1C levels guide explains how numbers are interpreted.
Questions to Ask Your Clinician
Before starting, consider asking:
- Do my A1C, BMI, or comorbidities make tirzepatide a reasonable option under FDA labeling?
- What side effects should prompt me to call you?
- How will we decide when to move from 2.5 mg to 5 mg?
- What is the plan if I cannot tolerate the starting dose?
Storage, Injection, and Follow-Up
Tirzepatide comes in single-dose pens or vials. Unopened pens are typically refrigerated, while in-use pens may be kept at room temperature for a labeled period. Injections go into the abdomen, thigh, or upper arm. Rotate sites to reduce injection-site reactions, and never share a pen or needle. Keep follow-up visits so your clinician can check labs, weight trends, and side effects.
The Bottom Line
The FDA-labeled starting dose of tirzepatide is 2.5 mg once weekly, held for four weeks before any titration. This is a tolerability step, not a maintenance dose. Whether tirzepatide is right for you, when to advance, and how to handle side effects are all decisions that belong in the exam room. Use this article as a reference, and follow the plan your clinician gives you. This content is educational and not medical advice.
